Relative Bioavailability of Two Different Batches of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet (FDC) in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial).
Phase of Trial: Phase I
Latest Information Update: 27 May 2014
At a glance
- Drugs Linagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 22 Apr 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 20 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2010 New trial record